Background: Sorafenib and sunitinib are tyrosine kinase inhibitors with largely overlapping specificities, approved for the treatment of metastatic renal-cell carcinoma (RCC). It was unclear whether the similarities of the two drugs would lead to complete cross-resistance, or whether sequential application would be efficacious. Methods: Patients with metastatic RCC and progression on sorafenib treatment were treated with repeated cycles of sunitinib, 50 mg for 4 weeks, followed by a 2-week break. Response (Response Evaluation Criteria in Solid Tumors, RECIST) was assessed every second cycle. Results: A total of 22 patients with progression on sorafenib were accrued. Initially, sorafenib treatment was efficacious in all patients, with 7 showing partial response (PR) and 15 stable disease (SD), and subsequent disease progression. With 4 PRs (18%) and 12 SD (55%) a disease control rate of 73% was achieved. The median progression-free survival (PFS) on sunitinib was 21.5 weeks; median overall survival (OS) was not reached. Estimated 1-year PFS and OS were 31 and 60%, respectively. There was no apparent relationship between response to sorafenib and outcome on sunitinib. Conclusion: In our cohort of patients with RCC and progression after initial efficacy of sorafenib, the efficacy data of second-line sunitinib were close to published results of first-line treatment, suggesting limited clinically relevant cross-resistance.

Motzer RJ, Bander NH, Nanus DM: Renal-cell carcinoma. N Engl J Med 1996;335:865–875.
Dvorak HF: Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368–4380.
Pantuck AJ, Zeng G, Belldegrun AS, et al: Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res 2003;9:4641–4652.
Escudier B: Advanced renal cell carcinoma: current and emerging management strategies. Drugs 2007;67:1257–1264.
Hudes G, Carducci M, Tomczak P, et al: Temsirolimus, interferon-α, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271–2281.
Linehan WM, Vasselli J, Srinivasan R, et al: Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin Cancer Res 2004;10(18 pt 2):6282–6289.
Mellado B, Gascón P: Molecular biology of renal cell carcinoma. Clin Transl Oncol 2006;8:706–710.
Motzer RJ, Bukowski RM: Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 2006;24:5601–5608.
Rini BI, Small EJ: Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005;23:1028–1043.
Schrader AJ, Olbert PJ, Hegele A, et al: Metastatic non-clear cell renal cell carcinoma: current therapeutic options. BJU Int 2008;101:1343–1345.
Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125–134. Erratum in: N Engl J Med 2007;357:203.
Grandinetti CA, Goldspiel BR: Sorafenib and sunitinib: novel targeted therapies for renal cell cancer. Pharmacotherapy 2007;27:1125–1144.
Grimaldi AM, Guida T, D’Attino R, et al: Bridging present and future cancer treatment. Ann Oncol 2007;6:31–34.
Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon-α in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115–124.
Motzer RJ, Michaelson MD, Redman BG, et al: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:1–3.
Motzer RJ, Rini BI, Bukowski RM, et al: Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516–2524.
Rini BI: Sunitinib. Expert Opin Pharmacother 2007;8:2359–2369.
Dham A, Dudek AZ: Sequential therapy with sorafenib and sunitinib in renal cell carcinoma (abstract 5106). J Clin Oncol 2007;25.
Sablin MP, Bouaita L, Balleyguier C, et al: Sequential use of sorafenib and sunitinib in renal cancer: retrospective analysis in 90 patients (abstract 5038). J Clin Oncol 2007;25.
Drucker BJ, Mazumdar M, Motzer RJ: Prognostic factors for metastatic kidney cancer. Cancer Treat Res 2003;116:139–153.
Motzer RJ, Bacik J, Mazumdar M: Prognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan-Kettering Cancer Center experience. Clin Cancer Res 2004;10(18 pt 2):6302–6303.
Motzer RJ, Bukowski RM: Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 2006;24:5601–5608.
Bhojani N, Jeldres C, Patard JJ, et al: Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008;53:917–930.
Radulovic S, Bjelogrlic SK: Sunitinib, sorafenib and mTOR inhibitors in renal cancer. J BUON 2007;12(suppl 1):151–162.
Tamaskar I, Garcia JA, Elson P, et al: Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 2008;179:81–86.
Stein MN, Flaherty KT: CCR drug updates: sorafenib and sunitinib in renal cell carcinoma. Clin Cancer Res 2007;13:3765–3770.
Zhong H, Bowen JP: Molecular design and clinical development of VEGFR kinase inhibitors. Curr Top Med Chem 2007;7:1379–1393.
Hajdenberg J, Oberoi S, Cohen N, et al: Evaluation of VEGF targeted therapy efficacy in mRCC after sorafenib failure or intolerance (abstract 15517). J Clin Oncol 2007;25.
Rini BI, Wilding GT, Hudes G, et al: Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib (abstract 5032). J Clin Oncol 2007;25.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.